Clinical Scorecard: Lonza to Acquire Five US CDMO Sites from Merck KGaA
At a Glance
| Category | Detail |
|---|---|
| Condition | Corporate acquisition of five US CDMO sites and associated businesses |
| Key Mechanisms | The transaction transfers five US sites and associated businesses to Lonza, covering bioconjugation, high-potency payload-linkers used in antibody-drug conjugates, viral vectors, lipid nanoparticles, liposomes, and PEGylated proteins. |
| Target Population | Pharmaceutical, biotechnology, and CDMO customers using the acquired services |
| Care Setting | US CDMO operations supporting products from clinical development through commercial manufacturing |
Key Highlights
- Lonza agreed to acquire five US CDMO sites from Merck KGaA; the transaction is expected to close in mid-2027, subject to regulatory approval and other customary conditions.
- Approximately 1,100 employees will transfer to Lonza, and its number of US manufacturing sites will increase from four to nine.
- The sites provide services across bioconjugation, high-potency payload-linkers used in antibody-drug conjugates, viral vectors, lipid nanoparticles, liposomes, and PEGylated proteins.
- The acquired businesses are expected to generate approximately CHF250 million in sales in 2028; their core EBITDA margin is expected to be initially below Lonza’s group average.
- Merck KGaA’s BioReliance Contract Testing Services business is excluded and will remain in its Life Science portfolio.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Not applicable; the article concerns a corporate acquisition of CDMO sites, not patient treatment.
No prescribing or treatment recommendations are reported. The acquired operations support development and manufacturing of complex modalities, including viral vectors and antibody-drug-conjugate components.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
